CTOs on the Move


 
Omicia is unlocking the potential of individualized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes. Researchers and clinical diagnostic organizations use our solutions to analyze and identify the genetic basis of a variety of conditions, including childhood disease, cancer and cardiovascular disease. Opal™, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data. VAAST, our robust novel disease gene finder and variant scoring algorithm, is in use at ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.omicia.com
  • 1625 Clay Street 2nd Floor
    Oakland, CA USA 94612
  • Phone: 510.595.0800

Executives

Name Title Contact Details

Funding

Omicia raised $23M on 06/09/2016

Similar Companies

B-Bridge International

B-Bridge International is a Cupertino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevai Labs

ELEVAI LABS, INC. is a biotechnology company developing cutting-edge regenerative skincare applications. The company solves the unmet needs in the regenerative aesthetics space through a combination of cutting-edge science and next-generation consumer applications. Elevai Labs develops state-of-the-art topic anesthetic and pharmaceutical-grade skin care for the physician-dispensed market, with a focus on leveraging stem cell exosome technology.

MGI PHARMA

MGI PHARMA, Inc. is a Lake Villa, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.

Alergan

Alergan is a Waco, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.